Table 1.
Patient characteristics and classification based on disease groups and anti-phospholipid syndrome (APS) clinical manifestations
| Patients | Characteristics | |||||||
|---|---|---|---|---|---|---|---|---|
| Number (n) of patients | 104 | |||||||
| Mean age in years | 40 (range 18–79) | |||||||
| Gender | Females (n) | 78 (75%) | ||||||
| Males (n) | 26 (25%) | |||||||
| Race | Caucasian (n) | 90 (79%) | ||||||
| Other* (n) | 14 (21%) | |||||||
| APS clinical manifestations | |||||||
|---|---|---|---|---|---|---|---|
| Disease groups (number, n) | VT (n = 19) | AT (n = 24) | Any TE (n = 40) | Toxaemia (n = 5) | Fetal demise (n = 5) | RPL (n = 8) | Any PRM (n = 14) |
| Primary APS (n = 8) | 5 | 4 | 8 | 1 | 1 | 0 | 1 |
| Secondary APS (n = 3) | 1 | 1 | 2 | 0 | 0 | 1 | 1 |
| SLE (n = 5) | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Non-SLE autoimmune diseases (n = 11) | 1 | 1 | 2 | 0 | 0 | 0 | 0 |
| Inherited thrombophilia (n = 2) | 0 | 2 | 2 | 0 | 0 | 0 | 0 |
| Idiopathic thrombosis (n = 15) | 5 | 10 | 15 | 0 | 0 | 0 | 0 |
| Equivocal LAC with APS manifestations (n = 8) | 2 | 3 | 5 | 0 | 1 | 3 | 3 |
| Any PRM with negative criteria laboratory tests for APS (n = 8) | 0 | 0 | 0 | 4 | 2 | 4 | 8 |
| Other clinical conditions (n = 44) | 4 | 3 | 6 | 0 | 1 | 0 | 1 |
*
Other included patients from diverse racial background or ethnicities with no definite majority. These include individuals of African American, Asian, Middle Eastern, non-Hispanic Latin American, Hawaiian/Pacific Island or undefined descent. VT = venous thrombosis; AT = arterial thrombosis; TE = any thrombotic event; RPL = recurrent pregnancy loss; any PRM = any pregnancy-related morbidity; SLE= systemic lupus erythematosus; LAC = lupus anti-coagulant.